Human Cytomegalovirus 65 kDa Phosphoprotein Market
Global Human Cytomegalovirus 65 kDa Phosphoprotein Market Size, Share & trends Report By Type (HB-101, CyMVectin, ASP-0113, and PepVax) and By Application (Brain Tumor, Hematological Tumor, Kidney Transplant Rejection, and liver Transplant Rejection) Forecast (2022-2028) Update Available - Forecast 2024-2030
The global human cytomegalovirus 65 kDa phosphoprotein market is anticipated to grow at a considerable CAGR during the forecast period. Human cytomegalovirus is a virus that causes lifelong infections in humans and is asymptomatic in healthy hosts. However, it can cause fatal diseases in individuals having a low immune system. The rise in HCMV is one of the factors accelerating the growth of the market. For instance, according to the British Society for Immunology, the HCMV is anticipated to have a prevalence of 55-100% within the human population, depending on different socioeconomic factors. Moreover, HCMV is the leading infectious cause of congenital abnormalities in the western world, affecting 1-1.25% of all live births. Thus, the rising prevalence of HCMV is anticipated to drive the growth of the global human cytomegalovirus 65 kDa phosphoprotein market during the forecast period.
Impact of COVID-19 Pandemic on Global Human Cytomegalovirus 65 kDa Phosphoprotein market
The COVID-19 Pandemic had resulted in a significant impact on the human cytomegalovirus 65 kDa phosphoprotein market. The restrictions and lockdowns have disrupted the supply chain owing to delayed business deals, especially in the area of pharmaceutical corporations. Moreover, the non–invasive surgeries were postponed to reallocate the resources to treat COVID-19 patients. Thus, factors such as lockdowns, restrictions, and social distancing have resulted in a negative impact on the global human cytomegalovirus 65 kDa phosphoprotein market.
Segmental Outlook
The global human cytomegalovirus 65 kDa phosphoprotein market is segmented based on type and application. Based on the type, the market is further sub-segmented into HB-101, CyMVectin, ASP-0113, and Pepvax. Based on the application, the market is further sub-segmented into the brain tumor, hematological tumor, kidney transplant rejection, and liver transplant rejection. Among these, the hematological tumor segment is anticipated to hold a considerable share in the market owing to the rise in the prevalence of brain tumors.
Global Human Cytomegalovirus 65 kDa Phosphoprotein Market by Type, 2021 (%)
HB-101 is Anticipated to Hold a Prominent share in the Global Human Cytomegalovirus 65 kDa Phosphoprotein market.
HB-101 is a bivalent recombinant vaccine against human CMV infection. HB-101 is anticipated to hold a prominent share in the global human cytomegalovirus 65 kDa phosphoprotein market owing to the rise in the prevalence of cytomegalovirus (CMV) infection. For instance, in 2020, according to the Center for Disease Control and Prevention (CDC), one in three children are already affected by CMV in the US. Moreover, over half of the adults have been infected with CMV by age 40. CDC further states that most people with CMV have no symptoms and potentially the individual may be reinfected with a different strain of the virus. Thus, owing to these factors, HB-101 is anticipated to play a significant role in minimizing the risk of CMV, further boosting the growth of the global human cytomegalovirus 65 kDa phosphoprotein market.
Regional Outlook
The global human cytomegalovirus 65 kDa phosphoprotein market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a considerable share in the market owing to the rise in healthcare infrastructure and healthcare spending.
Global Human Cytomegalovirus 65 kDa Phosphoprotein Market, by Region 2022-2028
North America Region is Anticipated to Hold Prominent Share in the Global human Cytomegalovirus 65 kDa Phosphoprotein Market
The North American region is anticipated to hold a prominent share in the global human cytomegalovirus 65 kDa phosphoprotein market owing to the rise in the incidence of brain tumors. According to the American Society for Clinical Oncology (ASCO), brain and nervous system tumor is the tenth leading cause of death for men and women. For instance, according to the data published by the American Society for Clinical Oncology (ASCO) in 2022, an estimated 308,102 people in the U.S, were diagnosed with brain or spinal cord tumors in 2020. Further, around 251,329 people died from primary cancerous brain and CNS tumors in 2020. Moreover, in 2022, about 4170 children under the age of 15 years are anticipated to be diagnosed with a brain tumor in the US. Thus, owing to the rising incidence of a brain tumor in the region, the human cytomegalovirus 65 kDa phosphoprotein market is anticipated to grow at a significant rate during the forecast period.
Market players Outlook
The major companies serving the global human cytomegalovirus 65 kDa phosphoprotein market are Astellas Pharma Inc, Hookipa Biotech AG, VBI Vaccines Inc, and more among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2021, Takeda Pharmaceuticals Co. Ltd had received the US Food and Drug Administration (FDA) has approval for Livtencity (maribavir). It is used to treat cytomegalovirus infections in adults and pediatric patients.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global human cytomegalovirus 65 kDa phosphoprotein market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Human Cytomegalovirus 65 kDa Phosphoprotein Market
- Recovery Scenario of The Global Human Cytomegalovirus 65 kDa phosphoprotein Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Astellas Pharma, Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. HOOPIKA Pharma, Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Immunomic Therapeutics Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. VBI Vaccines, Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. VAXIMM AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Human Cytomegalovirus 65 kDa Phosphoprotein Market by Type
4.1.1. HB-101
4.1.2. CyMVectin
4.1.3. Asp-0113
4.1.4. PepVax
4.2. Global Human Cytomegalovirus 65 kDa Phosphoprotein Market by Application
4.2.1. Brain Tumor
4.2.2. Hematological Tumor
4.2.3. Kidney Transplant Rejection
4.2.4. Liver Transplant Rejection
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AlloVir
6.2. AlphaVax
6.3. Helocyte, Inc.
6.4. Microbiotix, Inc.
6.5. Moderna, Inc.
6.6. Noble Pharmacare Ltd.
6.7. SL VaxiGen Inc.
6.8. SpyBiotech
6.9. Synklino A/S
6.10. Takeda Pharmacuetical Co.,Ltd.
1. GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL HB-101 IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL CYMVECTIN IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ASP-0113 IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL PEPVAX IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
7. GLOBAL BRAIN TUMOR IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL HEMATOLOGICAL TUMOR IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL KIDNEY TRANSPLANT REJECTION IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL LIVER TRANSPLANT REJECTION IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
15. EUROPEAN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY TYPE 2021-2028 ($ MILLION)
20. ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
21. REST OF THE WORLD HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET, 2022-2028 (%)
4. GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL HB-101 IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL CYMVECTIN IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL ASP-0113 IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL PEPVAX IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
10. GLOBAL BRAIN TUMOR IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL HEMATOLOGICAL TUMOR IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL KIDNEY TRANSPLANT REJECTION IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL LIVER TRANSPLANT REJECTION IN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. US HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
16. UK HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD HUMAN CYTOMEGALOVIRUS 65 KDA PHOSPHOPROTEIN MARKET SIZE, 2021-2028 ($ MILLION)
